Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases

Abstract

The present invention relates to substances which modulate receptors involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.

What is claimed is:  
     
         1 . A method for determining an expression level of an ILM receptor comprising: determining the level of ILM receptor expressed in a macrophage.  
     
     
         2 . The method according to  claim 1  in which said macrophage is a mammalian cell.  
     
     
         3 . The method according to  claim 2  in which said macrophage is a human cell.  
     
     
         4 . The method according to  claim 3  in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation.  
     
     
         5 . The method according to  claim 4  in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation in a mammal.  
     
     
         6 . The method according to  claim 5  in which the analysis is performed using a macrophage or a part thereof obtainable from the site of inflammation in a human being.  
     
     
         7 . The method according to  claim 1  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         8 . The method according to  claim 1  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         9 . The method according to  claim 1  in which said receptor is an FPRL-1 receptor type receptor.  
     
     
         10 . The method according to  claim 9  in which the FPRL-1 receptor type receptor is SEQ ID NO:2 or a variant, mutant, or fragment thereof having the same function.  
     
     
         11 . The method according to  claim 1  for diagnosis or monitoring of a chronic inflammatory airway disease.  
     
     
         12 . The method according to  claim 11  in which the chronic inflammatory airway disease is selected from the group consisting of chronic bronchitis and COPD.  
     
     
         13 . The method according to  claim 11  in which the macrophage or a part thereof is obtained from the site of inflammation.  
     
     
         14 . The method according to  claim 13  in which the macrophage or a part thereof is obtained from a site of inflammation in a mammal.  
     
     
         15 . The method according to  claim 14  in which the mammal is a human being.  
     
     
         16 . A test system kit for determining whether a substance is an activator or an inhibitor of an ILM receptor function wherein the receptor is involved in a chronic inflammatory airway disease and wherein the receptor plays a role in mediating inflammation comprising at least: 
 a. an ILM receptor, or    b. an expression vector capable of expressing an ILM receptor in a cell, or    c. a host cell transformed with an expression vector capable of expressing an ILM receptor.    
     
     
         17 . The test system kit according to  claim 16  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         18 . The test system kit according to  claim 16  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         19 . The test system kit according to  claim 16  in which said receptor is a FPRL-1 receptor type receptor.  
     
     
         20 . The test system kit according to  claim 19  in which the FPRL-1 receptor type receptor is SEQ ID NO 2 or a variant, mutant, or fragment thereof having the same function.  
     
     
         21 . The test system kit according to  claim 20  comprising a cell expressing an ILM receptor.  
     
     
         22 . The test system kit according to  claim 21  in which the cell is a MonoMac6 or a THP-1 cell, wherein said cell is stimulated with phorbol 12-myristate 13-acetate and with a substance selected from a group consisting of LPS and smoke.  
     
     
         23 . A substance determined to be an activator or inhibitor of an ILM receptor.  
     
     
         24 . The substance according to  claim 23  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         25 . The substance according to  claim 23  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         26 . The substance according to  claim 23  in which said receptor is an FPRL-1 receptor type receptor.  
     
     
         27 . The substance according to  claim 26  in which the FPRL-1 receptor type receptor is SEQ ID NO:2 or a variant, mutant, or fragment thereof having the same function.  
     
     
         28 . A substance which is an activator or inhibitor of an ILM receptor for the treatment of a disease.  
     
     
         29 . The substance according to  claim 28  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         30 . The substance according to  claim 28  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         31 . The substance according to  claim 28  in which said receptor is an FPRL-1 receptor type receptor.  
     
     
         32 . The substance according to  claim 31  in which the FPRL-1 receptor type receptor is SEQ ID NO:2 or a variant, mutant, or fragment thereof having the same function.  
     
     
         33 . The substance according to  claim 28  in which said disease is a chronic inflammatory airway disease.  
     
     
         34 . The substance according to  claim 33  in which said chronic inflammatory airway disease is selected from the group consisting of chronic bronchitis and COPD.  
     
     
         35 . A pharmaceutical composition comprising at least one substance determined to be an activator or inhibitor of an ILM receptor; and a pharmaceutically acceptable carrier.  
     
     
         36 . The pharmaceutical composition according to  claim 35  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         37 . The pharmaceutical composition according to  claim 35  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         38 . The pharmaceutical composition according to  claim 35  in which said receptor is an FPRL-1 receptor type receptor.  
     
     
         39 . The pharmaceutical composition according to  claim 38  in which the FPRL-1 receptor type receptor is SEQ ID NO:2 or a variant, mutant, or fragment thereof having the same function.  
     
     
         40 . A method for treating a chronic inflammatory airway disease comprising administering to a being in need of such treatment a suitable amount of a pharmaceutical composition comprising at least one substance determined to be an activator or inhibitor of an ILM receptor.  
     
     
         41 . The method according to  claim 40  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         42 . The method according to  claim 40  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         43 . The method according to  claim 40  in which said receptor is an FPRL-1 receptor type receptor.  
     
     
         44 . The method according to  claim 43  in which the FPRL-1 receptor type receptor is SEQ ID NO:2 or a variant, mutant, or fragment thereof having the same function.  
     
     
         45 . The method according to  claim 40  wherein the being is a mammal.  
     
     
         46 . The method according to  claim 45  wherein the being is a human being.  
     
     
         47 . The method according to  claim 40  for treating a chronic inflammatory airway disease selected from the group consisting of chronic bronchitis and COPD.  
     
     
         48 . A method for selectively modulating an ILM receptor in a macrophage comprising administering a substance determined to be an activator or inhibitor of an ILM receptor.  
     
     
         49 . The method according to  claim 48  in which the macrophage is involved in a chronic inflammatory airway disease.  
     
     
         50 . The method according to  claim 49  in which the chronic inflammatory airway disease is selected from the group consisting of chronic bronchitis and COPD  
     
     
         51 . The method according to  claim 48  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor type receptor, HM74 receptor type receptor, AICL receptor type receptor, ILT1 receptor type receptor, SHPS receptor type receptor, KDEL receptor 1 type receptor, and CSF-1 receptor type receptor.  
     
     
         52 . The method according to  claim 48  in which said receptor is a receptor selected from the group consisting of FPRL-1 receptor (SEQ ID NO:2), HM74 receptor (SEQ ID NO:21), AICL receptor (SEQ ID NO:6), ILT1 receptor (SEQ ID NO:12), SHPS-1 receptor (SEQ ID NO:4), KDEL receptor 1 (SEQ ID NO:8), and CSF-1 receptor (SEQ ID NO:10).  
     
     
         53 . The method according to  claim 48  in which said receptor is an FPRL-1 receptor type receptor.  
     
     
         54 . The method according to  claim 53  in which the FPRL-1 receptor type receptor is SEQ ID NO:2 or a variant, mutant, or fragment thereof having the same function.